SHANGHAI, Jan. 19,
2023 /PRNewswire/ -- Zhongchao Inc. (NASDAQ:
ZCMD) ("Zhongchao" or the "Company"), a platform-based internet
technology company offering services to patients with oncology and
other major diseases, today announced that Zhongxin Medical
Technology Co., Ltd. ("Zhongxin"), one of the China operating entities of which the Company
consolidates the financial results with through certain contractual
arrangements, launched the Medication Management Assistance Mini
Program on WeChat (the "Program") to assist cancer patients in
managing multiple issues during the medication and facilitate whole
treatment process.
Zhongxin launched the Program aiming to navigate and solve the
medication challenges faced by cancer patients. During cancer
treatment process, the use of one or more anti-tumor drugs,
especially targeted and immune drugs, will face various challenges,
including, among others, dosing punctuality, incorrect dosage,
missed dose, taking with other drugs and adverse reaction
management. If such challenges cannot be solved, the treatment
process will be negatively affected, and patients' confidence in
treatment could be undermined, ultimately affecting the curative
effect. In order to resolve medication-related challenges in a
timely manner and promote the continuity of treatment, Zhongxin
developed and designed the Program with several functions. The
Program can automatically remind patients to take medication and
precautions according to the characteristics of different cancers
and consumption time of medications. It can also provide general
self-treatment information based on the adverse reactions that
patients might have taking such medications and timely provide
corresponding self-treatment information for such adverse reactions
specifically encountered by patients during the medication
administration process. Additionally, the Program could train
patients' self-management ability through various illustrations and
video courses. Through the Program, patients can choose different
types of cancers and corresponding drugs to customize and
self-manage their medication process, and such convenience could
boost patients' confidence in their cancer treatment. Currently,
the Program only targets patients with lung cancer and kidney
cancer, and Zhongxin plans to expand to cover other cancers in the
future.
Weiguang Yang, Chairman and Chief
Executive Officer of Zhongchao, commented, "we are excited about
the launch of the Program. As cancer treatment technology, drugs
and solutions advance, patient-side knowledge and behaviors are
increasingly important during treatment process and have positive
effects on cancer treatment, we believe that by cultivating good
medication habits for patients and providing assistance to
patients, it will achieve maximum efficacy and improve cancer
treatment outcomes. We expect that the Program will further enhance
patient service experience and increase user loyalty. Going
forward, we will continue to improve our services offering to
better pursue our goal of contributing to improved cancer patient
treatment experience and outcomes."
About Zhongchao Inc.
Zhongchao Inc. is an offshore holding company incorporated in
the Cayman Islands. It conducts
operations in China through the
contractual arrangements between its wholly owned subsidiary and
PRC operating entities. Zhongchao Inc. is a platform-based internet
technology company offering services to patients with oncology and
other major diseases. The PRC operating entities provide online
healthcare information, professional training and educational
services to healthcare professionals under their "MDMOOC" platform
(www.mdmooc.org), offer patient management services in the
professional field of tumor and rare diseases through Zhongxin,
offer internet healthcare services through Zhixun Internet
Hospital, and pharmaceutical services through Xinjiang Medical and
operate an online information platform, Sunshine Health Forums, to
general public. More information about the Company can be found at
its investor relations website at http://izcmd.com.
Safe Harbor Statement
This press release contains forward-looking statements as
defined by the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include statements concerning plans,
objectives, goals, strategies, future events or performance, and
underlying assumptions and other statements that are other than
statements of historical facts. When the Company uses words such as
"may," "will," "intend," "should," "believe," "expect,"
"anticipate," "project," "estimate" or similar expressions that do
not relate solely to historical matters, it is making
forward-looking statements. Forward-looking statements are not
guarantees of future performance and involve risks and
uncertainties that may cause the actual results to differ
materially from the Company's expectations discussed in the
forward-looking statements. These statements are subject to
uncertainties and risks including, but not limited to, the
following: the Company's goals and strategies; the Company's
future business development; product and service demand and
acceptance; changes in technology; economic conditions; the growth
of the professional training and educational services market in
China and the other international
markets the Company plans to serve; reputation and brand; the
impact of competition and pricing; government regulations;
fluctuations in general economic and business conditions in
China and the international
markets the Company plans to serve and assumptions underlying or
related to any of the foregoing and other risks contained in
reports filed by the Company with the SEC, the length and severity
of the recent coronavirus outbreak, including its impacts across
our business and operations. For these reasons, among others,
investors are cautioned not to place undue reliance upon any
forward-looking statements in this press release. Additional
factors are discussed in the Company's filings with the SEC, which
are available for review at www.sec.gov. The Company undertakes no
obligation to publicly revise these forward–looking statements to
reflect events or circumstances that arise after the date
hereof.
For more information, please contact:
At the Company: Pei Xu, CFO
Email: xupei@mdmooc.org
Phone: +86 21-3220-5987
Investor Relations: Sherry Zheng
Weitian Group LLC
Email: shunyu.zheng@weitian-ir.com
Phone: +1 718-213-7386
View original
content:https://www.prnewswire.com/news-releases/zhongchao-inc-launches-medication-management-assistance-mini-program-to-facilitate-cancer-treatment-301725474.html
SOURCE Zhongchao Inc.
